BioPharma Dive
The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.
BioPharma Dive
The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.
BioPharma Dive
The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.